A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy.
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle spasticity
- Focus Registrational; Therapeutic Use
- Acronyms ELLIE
- Sponsors Merz Pharmaceuticals GmbH
Most Recent Events
- 29 Sep 2022 New trial record